Skip Navigation


JAC Advance Access originally published online on September 5, 2008
Journal of Antimicrobial Chemotherapy 2008 62(5):860-865; doi:10.1093/jac/dkn346
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
62/5/860    most recent
dkn346v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Wiegand, J.
Right arrow Articles by Wedemeyer, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wiegand, J.
Right arrow Articles by Wedemeyer, H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Leading articles

Treatment of acute hepatitis C: the success of monotherapy with (pegylated) interferon {alpha}

Johannes Wiegand1,*, Katja Deterding2, Markus Cornberg2 and Heiner Wedemeyer2

1 Department of Internal Medicine, Medical Clinic and Polyclinic II, University of Leipzig, Leipzig, Germany 2 Department of Gastroenterology, Hepatology and Endocrinology, Medical School Hannover, Hannover, Germany

* Corresponding author. Tel: +49-341-97-12226; Fax: +49-341-97-12228; E-mail: johannes.wiegand{at}medizin.uni-leipzig.de

Early control in the acute phase of hepatitis C infection is an attractive therapeutic goal in order to shorten disease duration and infectivity, to prevent chronicity and progression to advanced liver disease and to avoid eventual therapeutic non-response in the later stages of chronic hepatitis C. Over the past decade, different interferon-based treatment options have been developed, which lead to sustained virological response rates of up to 98%. The present article summarizes the successful invention of immediate and delayed strategies in acute hepatitis C monoinfection, critically discusses potential limitations and illustrates the therapeutic challenges of the near future.

Keywords: antiviral therapy , hepatology , liver disease


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.